PortalPublikationenCyclophosphamide-based stem cell mobilization in relapsed mu...

Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE

Standard

Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE. / Baertsch, Marc-Andrea; Schlenzka, Jana; Lisenko, Katharina; Krzykalla, Julia; Becker, Natalia; Weisel, Katja; Noppeney, Richard; Martin, Hans; Lindemann, Hans W; Haenel, Mathias; Nogai, Axel; Scheid, Christof; Salwender, Hans; Fenk, Roland; Graeven, Ullrich; Reimer, Peter; Schmidt-Hieber, Martin; Goerner, Martin; Schmidt-Wolf, Ingo G H; Klein, Stefan; Ho, Anthony D; Goldschmidt, Hartmut; Wuchter, Patrick.

in: EUR J HAEMATOL, Jahrgang 99, Nr. 1, 07.2017, S. 42-50.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Baertsch, M-A, Schlenzka, J, Lisenko, K, Krzykalla, J, Becker, N, Weisel, K, Noppeney, R, Martin, H, Lindemann, HW, Haenel, M, Nogai, A, Scheid, C, Salwender, H, Fenk, R, Graeven, U, Reimer, P, Schmidt-Hieber, M, Goerner, M, Schmidt-Wolf, IGH, Klein, S, Ho, AD, Goldschmidt, H & Wuchter, P 2017, 'Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE', EUR J HAEMATOL, Jg. 99, Nr. 1, S. 42-50. https://doi.org/10.1111/ejh.12888

APA

Baertsch, M-A., Schlenzka, J., Lisenko, K., Krzykalla, J., Becker, N., Weisel, K., Noppeney, R., Martin, H., Lindemann, H. W., Haenel, M., Nogai, A., Scheid, C., Salwender, H., Fenk, R., Graeven, U., Reimer, P., Schmidt-Hieber, M., Goerner, M., Schmidt-Wolf, I. G. H., ... Wuchter, P. (2017). Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE. EUR J HAEMATOL, 99(1), 42-50. https://doi.org/10.1111/ejh.12888

Vancouver

Baertsch M-A, Schlenzka J, Lisenko K, Krzykalla J, Becker N, Weisel K et al. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE. EUR J HAEMATOL. 2017 Jul;99(1):42-50. https://doi.org/10.1111/ejh.12888

Bibtex

@article{79fee60121e249c1b77ff4f8305f1ceb,
title = "Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE",
abstract = "OBJECTIVE: Analysis of the efficiency and toxicity of cyclophosphamide-based stem cell mobilization in patients with relapsed multiple myeloma (RMM).METHODS: Peripheral blood stem cells (PBSCs) were mobilized with high dose cyclophosphamide (2 g/m2 daily on days 1 and 2) and G-CSF plus pre-emptive/rescue plerixafor in RMM patients (first to third relapse) treated within the ReLApsE trial of the German-Speaking Myeloma Multicenter Group (GMMG).RESULTS: Mobilization was initiated with high-dose cyclophosphamide (HD-CY) and G-CSF in 30 patients. Fifteen patients received additional pre-emptive/rescue administration of plerixafor. Stem cell collection was successful (≥2×106 CD34+ cells per kg bw) in 77% (23/30 patients). Patients with prior high-dose melphalan collected a significantly lower median total number of PBSCs than patients without prior high-dose melphalan (3.3×106 vs 17×106 CD34+ cells/kg bw). Toxicity of HD-CY was frequent with 12 serious adverse events (SAE) in 37% of patients (11/30 patients). Infections accounted for the majority of SAE reports. In two patients, SAEs were lethal (septic shock).CONCLUSIONS: These data proof feasibility of PBSC collection at relapse but emphasize the importance of collection and storage of additional PBSC transplants during first-line treatment when mobilization is more efficient and less toxic.",
keywords = "Adult, Aged, Cyclophosphamide, Female, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Multiple Myeloma, Peripheral Blood Stem Cells, Recurrence, Time-to-Treatment, Transplantation, Autologous, Treatment Outcome, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial",
author = "Marc-Andrea Baertsch and Jana Schlenzka and Katharina Lisenko and Julia Krzykalla and Natalia Becker and Katja Weisel and Richard Noppeney and Hans Martin and Lindemann, {Hans W} and Mathias Haenel and Axel Nogai and Christof Scheid and Hans Salwender and Roland Fenk and Ullrich Graeven and Peter Reimer and Martin Schmidt-Hieber and Martin Goerner and Schmidt-Wolf, {Ingo G H} and Stefan Klein and Ho, {Anthony D} and Hartmut Goldschmidt and Patrick Wuchter",
note = "{\textcopyright} 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2017",
month = jul,
doi = "10.1111/ejh.12888",
language = "English",
volume = "99",
pages = "42--50",
journal = "EUR J HAEMATOL",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE

AU - Baertsch, Marc-Andrea

AU - Schlenzka, Jana

AU - Lisenko, Katharina

AU - Krzykalla, Julia

AU - Becker, Natalia

AU - Weisel, Katja

AU - Noppeney, Richard

AU - Martin, Hans

AU - Lindemann, Hans W

AU - Haenel, Mathias

AU - Nogai, Axel

AU - Scheid, Christof

AU - Salwender, Hans

AU - Fenk, Roland

AU - Graeven, Ullrich

AU - Reimer, Peter

AU - Schmidt-Hieber, Martin

AU - Goerner, Martin

AU - Schmidt-Wolf, Ingo G H

AU - Klein, Stefan

AU - Ho, Anthony D

AU - Goldschmidt, Hartmut

AU - Wuchter, Patrick

N1 - © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2017/7

Y1 - 2017/7

N2 - OBJECTIVE: Analysis of the efficiency and toxicity of cyclophosphamide-based stem cell mobilization in patients with relapsed multiple myeloma (RMM).METHODS: Peripheral blood stem cells (PBSCs) were mobilized with high dose cyclophosphamide (2 g/m2 daily on days 1 and 2) and G-CSF plus pre-emptive/rescue plerixafor in RMM patients (first to third relapse) treated within the ReLApsE trial of the German-Speaking Myeloma Multicenter Group (GMMG).RESULTS: Mobilization was initiated with high-dose cyclophosphamide (HD-CY) and G-CSF in 30 patients. Fifteen patients received additional pre-emptive/rescue administration of plerixafor. Stem cell collection was successful (≥2×106 CD34+ cells per kg bw) in 77% (23/30 patients). Patients with prior high-dose melphalan collected a significantly lower median total number of PBSCs than patients without prior high-dose melphalan (3.3×106 vs 17×106 CD34+ cells/kg bw). Toxicity of HD-CY was frequent with 12 serious adverse events (SAE) in 37% of patients (11/30 patients). Infections accounted for the majority of SAE reports. In two patients, SAEs were lethal (septic shock).CONCLUSIONS: These data proof feasibility of PBSC collection at relapse but emphasize the importance of collection and storage of additional PBSC transplants during first-line treatment when mobilization is more efficient and less toxic.

AB - OBJECTIVE: Analysis of the efficiency and toxicity of cyclophosphamide-based stem cell mobilization in patients with relapsed multiple myeloma (RMM).METHODS: Peripheral blood stem cells (PBSCs) were mobilized with high dose cyclophosphamide (2 g/m2 daily on days 1 and 2) and G-CSF plus pre-emptive/rescue plerixafor in RMM patients (first to third relapse) treated within the ReLApsE trial of the German-Speaking Myeloma Multicenter Group (GMMG).RESULTS: Mobilization was initiated with high-dose cyclophosphamide (HD-CY) and G-CSF in 30 patients. Fifteen patients received additional pre-emptive/rescue administration of plerixafor. Stem cell collection was successful (≥2×106 CD34+ cells per kg bw) in 77% (23/30 patients). Patients with prior high-dose melphalan collected a significantly lower median total number of PBSCs than patients without prior high-dose melphalan (3.3×106 vs 17×106 CD34+ cells/kg bw). Toxicity of HD-CY was frequent with 12 serious adverse events (SAE) in 37% of patients (11/30 patients). Infections accounted for the majority of SAE reports. In two patients, SAEs were lethal (septic shock).CONCLUSIONS: These data proof feasibility of PBSC collection at relapse but emphasize the importance of collection and storage of additional PBSC transplants during first-line treatment when mobilization is more efficient and less toxic.

KW - Adult

KW - Aged

KW - Cyclophosphamide

KW - Female

KW - Granulocyte Colony-Stimulating Factor

KW - Hematopoietic Stem Cell Mobilization

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Peripheral Blood Stem Cells

KW - Recurrence

KW - Time-to-Treatment

KW - Transplantation, Autologous

KW - Treatment Outcome

KW - Clinical Trial, Phase III

KW - Journal Article

KW - Randomized Controlled Trial

U2 - 10.1111/ejh.12888

DO - 10.1111/ejh.12888

M3 - SCORING: Journal article

C2 - 28370401

VL - 99

SP - 42

EP - 50

JO - EUR J HAEMATOL

JF - EUR J HAEMATOL

SN - 0902-4441

IS - 1

ER -